Section 4: Prescription

Didier’s physician has decided to start him on a PI-based regimen


Boosted PIs in ARV-naïve patients: Virological suppression at 48 weeks

case didier graph 4

Adapted from: 1. Eron J, et al. Lancet 2006;368:476–482; 2. Walmsley S, et al JAIDS 2009 Feb 12. [Epub ahead of print], 3. Molina J-M, et al. Lancet 2008;372:646–655 4. Gathe J, et al. JAIDS 2009 Feb 16. [Epub ahead of print];


CASTLE primary efficacy endpoint at Week 48: HIV RNA <50 c/mL (ITT-CVR NC=F)

case didier graph 5

Adapted from Molina J-M, et al. Lancet 2008;372:646–655


CASTLE primary efficacy endpoint at Week 96: HIV RNA <50 c/mL (ITT-CVR NC=F)

case didier graph 6

Molina J-M, et al. ICAAC/IDSA, Washington, USA, 2008, Poster H-1250d


CASTLE ITT-confirmed virological response (NC=F) by qualifying HIV viral load

case didier graph 7

Adapted from Molina J-M, et al. Lancet 2008;372:646–655 2 Molina J-M, et al. ICAAC/IDSA, Washington, USA, 2008, Poster H-1250d


PI/r in treatment experienced patients: DRV/r or TPV/r vs. cPI(s): Viral load <50 copies/mL by ENF use at 48 weeks

case didier graph 8

Adapted from Hill A and Moyle. 46th ICAAC, San Francisco, CA, Sept. 27-30, 2006; Abst. H-1386.